CD274 and non-small cell lung carcinoma: The CheckMate-026 trial compared nivolumab to standard-of-care chemotherapy in first-line treatment of advanced or recurrent NSCLC with PD-L1 positivity ≥5% and did not demonstrate a significant survival benefit for nivolumab [30].